Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2017-09-28
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EF03
|
| gptkbp:brand |
gptkb:Verzenio
|
| gptkbp:CASNumber |
1231929-97-7
|
| gptkbp:chemicalFormula |
C27H32F2N8
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:eliminationHalfLife |
18 hours
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:abemaciclib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Verzenio
|
| gptkbp:indication |
gptkb:cancer
HR-positive, HER2-negative advanced or metastatic breast cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
CDK4/6 inhibitor
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:proteinBinding |
96.3%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain fatigue infections neutropenia |
| gptkbp:bfsParent |
gptkb:礼来公司
gptkb:Eli_Lilly_and_Company |
| gptkbp:bfsLayer |
5
|